標(biāo)題: Titlebook: Quantitative Decisions in Drug Development; Christy Chuang-Stein,Simon Kirby Book 2021Latest edition The Editor(s) (if applicable) and The [打印本頁] 作者: Fillmore 時間: 2025-3-21 20:07
書目名稱Quantitative Decisions in Drug Development影響因子(影響力)
書目名稱Quantitative Decisions in Drug Development影響因子(影響力)學(xué)科排名
書目名稱Quantitative Decisions in Drug Development網(wǎng)絡(luò)公開度
書目名稱Quantitative Decisions in Drug Development網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Quantitative Decisions in Drug Development被引頻次
書目名稱Quantitative Decisions in Drug Development被引頻次學(xué)科排名
書目名稱Quantitative Decisions in Drug Development年度引用
書目名稱Quantitative Decisions in Drug Development年度引用學(xué)科排名
書目名稱Quantitative Decisions in Drug Development讀者反饋
書目名稱Quantitative Decisions in Drug Development讀者反饋學(xué)科排名
作者: Arresting 時間: 2025-3-21 21:51
Christy Chuang-Stein,Simon Kirbyeresse ist.Includes supplementary material: .Der Markt spornt Menschen und Unternehmen zur Leistung an. Er sichert die Güterversorgung und bewirkt wie durch eine unsichtbare Hand, dass der Eigennutz des Einzelnen auch dem Nutzen der anderen dient. In diesem Buch wird gezeigt, wie, unter welchen Vora作者: abreast 時間: 2025-3-22 02:18
Christy Chuang-Stein,Simon Kirbyeresse ist.Includes supplementary material: .Der Markt spornt Menschen und Unternehmen zur Leistung an. Er sichert die Güterversorgung und bewirkt wie durch eine unsichtbare Hand, dass der Eigennutz des Einzelnen auch dem Nutzen der anderen dient. In diesem Buch wird gezeigt, wie, unter welchen Vora作者: fibula 時間: 2025-3-22 05:27 作者: canvass 時間: 2025-3-22 11:06 作者: bioavailability 時間: 2025-3-22 15:33 作者: 信任 時間: 2025-3-22 17:03
Christy Chuang-Stein,Simon Kirbylurgie erreicht worden. Grundlage aller Betrachtungen zum Verhalten von metallischen Fremdk?rpern zur Stabilisierung von Frakturen sind zun?chst einmal die grunds?tzlichen mechanischen Eigenschaften der Implantate selbst. Diese werden definiert durch ihre Verformbarkeit unter Belastung, also der Deh作者: Needlework 時間: 2025-3-23 00:32
Christy Chuang-Stein,Simon Kirbyixation wie Gips oder unilateraler Fixateur externe l??t eine interfragment?re Bewegung bei gleichzeitiger Gewichtsbelastung zu. Somit wird eine Frakturheilung unter dynamischen Bedingungen erzeugt. Eine eher starre Fixation wie interne Verplattung reduziert diese Bewegung erheblich und sorgt für ei作者: 你正派 時間: 2025-3-23 02:51 作者: candle 時間: 2025-3-23 08:22 作者: 碎片 時間: 2025-3-23 10:27
Christy Chuang-Stein,Simon Kirbytung des Femur in varischer Abknickung, gemessen in mm oder bei Torsionsbeanspruchung, gemessen in Grad. Tats?chlich wirken auf Implantate im Knochen jedoch nicht nur die Kr?fte in axialer oder direkt seitlicher bzw. reiner Drehrichtung, es liegen immer gemischte Krafteinflüsse auf den Implantat-Kno作者: 評論者 時間: 2025-3-23 15:03 作者: vector 時間: 2025-3-23 20:47 作者: 不確定 時間: 2025-3-23 22:58 作者: slipped-disk 時間: 2025-3-24 03:19
e.Sie wirken zurück auf das Verhalten der Akteure, l?sen die Dynamik der M?rkte aus und bestimmen die wirtschaftliche Entwicklung. .Das Buch zeigt den Einfluss der Marktordnung auf den Güter- und Finanzm?rkten,978-3-662-46783-1作者: set598 時間: 2025-3-24 07:56 作者: 抗原 時間: 2025-3-24 12:08
Christy Chuang-Stein,Simon Kirbysagen der Selbstregelung des Marktes bei Engp?ssen und S?ttigung. Auch die M?glichkeiten und Grenzen der Geld-, Finanz-, Steuer- und Wirtschaftspolitik werden unter dem Aspekt des Marktes besser978-3-540-72598-5Series ISSN 2512-5281 Series E-ISSN 2512-529X 作者: Strength 時間: 2025-3-24 18:53 作者: 徹底檢查 時間: 2025-3-24 19:33 作者: 鈍劍 時間: 2025-3-25 01:40
Book 2021Latest editioncal data in the design and analysis of clinical trials, and extending decision criteria tothe cases when the primary endpoint is binary. The examples used to illustrate the additional materials all come from real trials with some post-trial reflections offered by the authors. ..The book begins with 作者: SNEER 時間: 2025-3-25 04:32
Christy Chuang-Stein,Simon KirbyFocuses on important decision points and evidence needed for making decisions at these points during the development of a new drug.Takes a holistic approach towards drug development by incorporating k作者: DEMN 時間: 2025-3-25 07:31 作者: 四海為家的人 時間: 2025-3-25 13:32
Quantitative Decisions in Drug Development978-3-030-79731-7Series ISSN 2366-8695 Series E-ISSN 2366-8709 作者: vertebrate 時間: 2025-3-25 17:47 作者: opprobrious 時間: 2025-3-25 20:02
https://doi.org/10.1007/978-3-030-79731-7clinical trials; metric for decision; drug development; probability of study success; probability of pro作者: 不連貫 時間: 2025-3-26 03:42
Book 2021Latest editions a holistic approach towards drug development by incorporating explicitly knowledge learned from the earlier part of the development and available historical information into decisions at later stages. In addition, the book shares lessons learned from several select examples published in the litera作者: Ablation 時間: 2025-3-26 04:47 作者: Working-Memory 時間: 2025-3-26 10:42
Incorporating Information from Completed Trials and Other Sources in Future Trial Planning,ssurance probabilities under some definitions of success. We can use simulations to estimate these probabilities when closed-form expressions do not exist. With the use of prior distributions for the parameters of interest, we show how to assess the positive and negative predictive values of a design with its companion decision rule.作者: FUSC 時間: 2025-3-26 13:21
,Designing Dose–Response Studies with Desired Characteristics,nse study design, for both continuous and binary endpoints. We include an example of dose–response studies for an investigational medicinal product to illustrate the importance of covering an adequate dose range in dose-ranging studies.作者: 舞蹈編排 時間: 2025-3-26 19:16
Discounting Prior Results to Account for Selection Bias,e power of the subsequent Phase 3 trial if a Phase 3 trial is to be conducted. While we have hinted at the existence of selection bias in earlier chapters, Chapter 12 is the first time we consider this issue thoroughly. We offer some recommendations on how to watch out for selection bias when planning for late-stage trials.作者: extinguish 時間: 2025-3-26 21:27
A Frequentist Decision-Making Framework,. Procedures for assessing evidence and making decisions under the Frequentist approach are calibrated by how they would perform were they used repeatedly. We discuss challenges associated with the interpretation of .-values in the presence of multiplicity and selective inference.作者: menopause 時間: 2025-3-27 04:48 作者: 未完成 時間: 2025-3-27 08:15 作者: 自然環(huán)境 時間: 2025-3-27 11:08
Characteristics of a Diagnostic Test,view the metrics commonly used to characterize the performance of a diagnostic test. We then discuss what it means when a diagnostic test returns a positive or a negative result. We illustrate the discussion with the use of several decision rules.作者: detach 時間: 2025-3-27 17:31
Clinical Testing of a New Drug,d for emergency use through extensive public–private partnerships and the adoption of a high-risk business model. We offer some examples of recent advances in clinical trial designs and conclude the chapter with a short summary of the salient points covered in the chapter.作者: 等待 時間: 2025-3-27 20:31
The Parallel Between Clinical Trials and Diagnostic Tests,reproducibility is briefly discussed. We end the chapter by highlighting the difference between statistical power and the probability of a positive trial. This last point becomes more important as a new drug moves through the various development stages as will be illustrated in Chap. ..作者: MITE 時間: 2025-3-28 00:00
Designing Proof-of-Concept Trials with Desired Characteristics, can be considered as special cases of the LPDAT approach. We review the metrics introduced in Chap. . in the context of these five design types. We show how prior information on historical controls can be used to help plan a POC study and share an example on this application involving a rare disease.作者: Epidural-Space 時間: 2025-3-28 05:40
Designing Confirmatory Trials with Desired Characteristics,e hypothesis-testing perspective. In addition, we discuss factors that could affect POSS and how these factors should be incorporated into the planning of the confirmatory program. The chapter highlights the importance of a robust investment in Phase 2 development in order to achieve a desirable level of POSS at the Phase 3 stage.作者: hurricane 時間: 2025-3-28 09:53 作者: subacute 時間: 2025-3-28 11:50 作者: Dna262 時間: 2025-3-28 16:17
Additional Topics,ata. We also extend the concept of study success to regulatory and technical success. We wrap up the book by sharing the story of dabigatran where a higher dose of the drug, and not a lower dose, was approved based on an overall benefit–risk assessment.作者: LAVE 時間: 2025-3-28 20:22 作者: habitat 時間: 2025-3-29 01:32
A Frequentist Decision-Making Framework,velopment, the two actions correspond to progressing or not progressing a drug for further development. These two actions are fundamental to decision making in drug development. The Frequentist approach to statistical inference involves examining probability via its long-run frequency interpretation作者: CURL 時間: 2025-3-29 03:19 作者: FEMUR 時間: 2025-3-29 09:57 作者: 哭得清醒了 時間: 2025-3-29 11:59
Incorporating Information from Completed Trials and Other Sources in Future Trial Planning,consider the Bayesian approach to incorporate existing information into future trial planning. Under the Bayesian approach, prior distributions are used to describe the accumulated knowledge about unknown parameters such as responses to controls in previous trials and estimates pertaining to treatme作者: 博識 時間: 2025-3-29 16:04 作者: Compassionate 時間: 2025-3-29 22:55 作者: 帳單 時間: 2025-3-30 02:13 作者: 愚笨 時間: 2025-3-30 07:11 作者: confide 時間: 2025-3-30 12:07 作者: Corral 時間: 2025-3-30 14:32
Other Metrics That Have Been Proposed to Optimize Drug Development Decisions,into their decision process. In this chapter, we review two approaches that have been proposed to quantitatively incorporate cost into design considerations. The first one optimizes a benefit–cost efficiency score that measures the cost-effectiveness of a proof-of-concept trial design. The second ap作者: Heart-Rate 時間: 2025-3-30 20:06 作者: Neutropenia 時間: 2025-3-30 23:39 作者: 離開就切除 時間: 2025-3-31 04:54
Additional Topics,ssessment of program-level success probability when a program includes multiple studies in different phases of a disease, joint analysis of efficacy and safety endpoints, using prior information at the pre-clinical stage, and sources for data and information. We caution about changes in statistical 作者: 賠償 時間: 2025-3-31 05:46
